NLRP3 and Autoimmunity: Direct NLRP3 inhibitors, caspase-1 inhibitors, and purinergic (P2X7) antagonists are newer options for selected inflammasome-driven disease [4,12,14,15,16,17], and upstream TLR antagonists and cGAS–STING pathway modulators are in development for treating sterile inflammation and autoimmunity [7].